Summary
The aim of this study was to investigate whether there is a variable responsiveness of the hepatitis C virus and/or of the affected host to different types of interferon. We treated 21 patients affected by chronic hepatitis C who failed to respond to recombinant alpha interferon, after a four-month interval, with lymphoblastoid interferon.
Alanine transaminase (ALT) serum level was normal in 9 patients (43%) at the end of treatment. At the end of a 12 months treatment-free follow-up serum ALT remained normal in 3 patients, 4 patients relapsed and 2 dropped-out.
As yet there are no reports of differences in the therapeutic efficacy of the two types of interferon used in our study. The good response to the lymphoblastoid interferon in our non responders to recombinant alpha interferon may be due to the immune modulation induced by the four-month wash-out interval between the two therapies or to a different virus sensitivity to this interferon.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Peters M, Davis GL, Dooley JS, Hoofnagle JH (1986) The interferon system in acute and chronic viral hepatitis. In: Popper H, Schaffer F (eds) Progress in liver disease, vol 8. Grune and Stratton, New York, pp 453–467
Davis GL, Hoofnagle JH (1986) Interferon in viral hepatitis: role in pathogenesis and treatment. Hepatology 1038–1041
Davis GL, Baiart LA, Schiff ER, Lindsay KL, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, The Hepatitis Interventional Therapy (HIT) Group (1989) Treatment of chronic hepatitis C with recombinant alpha interferon. A multicenter randomized, controlled trial. N Engl J Med 321: 1501–1506
Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH (1989) Recombinant interferon alpha therapy for chronic hepatitis C. N Engl J Med 321: 1506–1510
Hoofnagle JH, Mullen KD, Jones DP, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones A (1986) Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon. N Engl Med 315: 1575–1578
Thomson AJ, Doran M, Lever AML, Webster ADB (1987) Alpha interferon therapy for non-A non-B Hepatitis transmitted by gammaglobulin replacement therapy. Lancet 1: 539–541
Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas HC (1989) Randomized controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. Br Med J 298: 80–82
Gömez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V (1990) Prolonged treatment (18 months) of chronic hepatitis C with recombinant alfa- interferon in comparison with a control group. J Hepatol 11 [Suppl 1]: S63–S67
Tine F, Magrin S, Craxi A, Pagliaro L (1991) Interferon for non-A non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol 13: 192–199
Marcellin P, Boyer N, Giosta E, Degotte C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP (1991) Recombinant human alfa-interferon in patients with chronic non A, non B hepatitis: a multicenter randomized controlled trial from France. Hepatology 13: 393–397
Cimino L, Nardone G, Citarella C, Perna E, Capuano G, Budillon G (1991) Treatment of chronic hepatitis C with recombinant interferon alfa. Ital J Gastroenterol 23: 399–402
Causse X, Godinot H, Chevallier M, Chossergross P, Zoulim F, Ouzan D, Heyraud JP, Fontanges, Albrecht J, Meschievitz C, Trepo C (1991) Comparison of 1 or 3MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101: 497–502
Di Bisceglie AM, Hoofnagle JH (1991) Therapy of chronic hepatitis C with alpha- interferon: the answer? Or more questions? Hepatology 13: 601–603
Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, Tamburro J, Schiff ER, Carey W, Payne J, Jacobson IM, Van Thiel DH, Lefkowitch J, The Hepatitis Interventional Therapy (HIT) Group (1990) Predictors of response to recombinant alpha interferon (rIFN) treatment in patients with chronic hepatitis C ( Abstract ). Hepatology 12: 905
Lindsay KL, Davis GL, Bodenheimer HC, Albrecht J, Balart LA, Perrillo RP; Dienstag JL, Tamburro C, Schiff ER, Carey W, Payne J, Jacobson IM, Van Thiel DH, Lefkowitch J, The Hepatitis Interventional Therapy Group (1990) Predictors of relapse and response to re-treatment in patients with an initial response to recombinant alpha interferon (rIFN) therapy for chronic hepatitis C ( Abstract ). Hepatology 12: 847
Antonelli G, Currenti M, Turriziani O, Dianzani F (1991) Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparation. J Infect Dis 163: 882–885
Marcellin P, Boyer N, Castelnau C, Degos F, Martinot M, Loriot MA, Erlinger S, Benhamou JP (1991) Retreatment with recombinant alpha interferon in patients with chronic hepatitis C ( Abstract ). Gastroenterology 100: 771
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag
About this paper
Cite this paper
Budillon, G., Cimino, L., D’Ascoli, B., Napolitano, P.V. (1993). Lymphoblastoid interferon in chronic hepatitis C patients who were “non responders” to recombinant interferon alpha (rIFN alpha). In: Gerlich, W.H. (eds) Research in Chronic Viral Hepatitis. Archives of Virology Supplementum, vol 8. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9312-9_25
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9312-9_25
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82497-9
Online ISBN: 978-3-7091-9312-9
eBook Packages: Springer Book Archive